COPD

Hanania explains how IL-33 inhibitors including itepekimab and astegolimab may uniquely benefit COPD exacerbation.

Discover how precision medicine reshapes COPD treatment, focusing on inflammation and patient-specific traits for improved outcomes in airway diseases.

Halpin reviews the state of triple therapy inhaler prescribing strategies in the era of new biologic options.

COPD management evolves with biologics, emphasizing personalized care and treatable traits to improve patient outcomes and address ongoing challenges.

COPD management evolves with targeted biologic therapies, enhancing treatment precision and improving patient outcomes in respiratory care.

Following CHEST 2025, Hanania discusses the progress being made toward more tailored, patient-oriented care in airway disorders.

Despite clinical definitions suggesting patients recover from exacerbations within 2 weeks of hospital discharge, most patients in a qualitative survey believed they had not achieved recovery within 3 months.

Experts explore the evolution of asthma and COPD treatments with targeted biologic therapies.

Bhatt discussed the latest data from a post-hoc analysis of the BOREAS and NOTUS trials.

Q3 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.

Cytisinicline shows promise as a safe and effective smoking cessation treatment, significantly improving quit rates in COPD.

Baseline emphysema detected in low-dose CT scans predicts long-term mortality in asymptomatic adults.

Discover how precision medicine and advanced biologics are revolutionizing COPD and asthma management, enhancing patient outcomes and quality of life.

Clinicians explore the evolving landscape of asthma and COPD treatment, emphasizing the role of biologics and biomarkers in personalized patient care.

July 2025 saw a number of updates in COPD management and new research on RSV and COVID.

In this video, the fifth in a 6-part series, panelists discuss the factors that influence initiating biologics for COPD.

In this video, the fourth in a 6-part series, panelists discuss how future studies of monoclonal antibodies in COPD could be refined.

In this video, the third in a 6-part series, panelists discuss how learnings from asthma management are informing COPD management.

In this video, the second in a 6-part series, panelists discuss using monoclonal antibodies in early-line COPD treatment.

In this video, the first in a 6-part series, panelists discuss the impact of monoclonal antibodies for COPD management.

Experts discuss the evolving management of asthma and COPD.

Genentech reveals mixed results for astegolimab in COPD trials, highlighting challenges in treatment options for this serious respiratory disease.

Explore how advanced practice practitioners enhance COPD care through innovative models, improving patient outcomes and addressing rural healthcare challenges.

Explore the latest advancements in pulmonology, including FDA approvals and breakthrough therapies for COPD, PAH, and rare respiratory diseases.

A form of the cytisine regimen, widely used in Eastern Europe for decades, is finally being put in front of US regulators after recently also becoming available in the UK.